08:00
Welcome and Introductions
Camille N. Kotton (US)
Takeda Corporate Breakfast Symposium on Illuminated constellations: How diverse institutional experiences guide practical CMV management
Chair
Camille N. Kotton (US)
Supported by
Description
This symposium aims to advance clinical care by discussing updated guidelines for managing refractory/resistant CMV and intolerant patient populations in post-transplant settings. The symposium will highlight the clinical relevance of early CMV identification and robust viral load monitoring, enabling recognition of refractory signals, assessment of viral kinetics, detection of recurrence patterns, and supporting timely clinical decision-making in patients with resistant, refractory and treatment-intolerant CMV. Insights from emerging real-world data and clinical trial evidence will also be explored to evaluate the role of newer anti-CMV agents, including maribavir, in contemporary practice. Through case studies, the audience will explore the potential impact of maribavir on intervention strategies in complex patients.
Presentations
08:00
08:03
Evidence informing earlier action in CMV management
Camille N. Kotton (US)
08:09
Recognizing refractory CMV signals early after transplant
Gang Huang (CN)
08:24
Managing patients when conventional therapy isn’t tolerated
Glen P. Westall (AU)
08:39
How evolving guidelines illuminate day-to-day clinical practice
Camille N. Kotton (US)
08:49
Panel discussion and Conclusion remaks
Camille N. Kotton (US)